Drugs that contain Amphetamine
1. Drug name - ADZENYS ER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9017731 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
| US9265737 | NEOS THERAPS INC | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
| US8709491 | NEOS THERAPS INC | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1.25MG BASE/ML | SUSPENSION, EXTENDED RELEASE;ORAL | Discontinued |
2. Drug name - ADZENYS XR-ODT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840924 | NEOS THERAPS | Compositions and methods of making rapidly dissolving ionically masked formulations |
Apr, 2026
(3 years from now) | |
| US9265737 | NEOS THERAPS | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles |
Jun, 2032
(9 years from now) | |
| US9017731 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
| US8709491 | NEOS THERAPS | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles |
Jun, 2032
(9 years from now) | |
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 3.1MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
| EQ 6.3MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
| EQ 9.4MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
| EQ 12.5MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
| EQ 15.7MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
| EQ 18.8MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.